CytomX announces $5M milestone triggered in Astellas Pharma TCB collaboration

CytomX Therapeutics (CTMX) announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas (ALPMF), triggering a $5M milestone payment to CytomX. CytomX and Astellas are collaborating on multiple conditionally activated TCB programs with CytomX eligible to receive additional future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets. “The achievement of clinical candidate nomination for the second Probody( TCB program in our broad collaboration with Astellas underscores our capabilities in the exciting field of conditionally activated, masked T-cell engaging bispecifics. …We are delighted with the progress in our broad alliance in this area with CytomX and look forward to the continued collaboration successes as we expand our next-generation immuno-oncology therapeutic pipeline to address areas of high unmet medical need.”